Value Line Low Total Return Screen (4/12/2013)

Photo Credit: bayat via Compfight cc

Companies of Interest

This week’s short list is the type of list we start to see near market tops. Several of the companies fail to reach the top quality quintile (Quality Ranking > 80) and we included AFLAC (AFL) although it’s on the edge.

We’ll be spending more time this month with Teva Pharma (TEVA) and the generic pharma industry to examine the bigger picture and longer term expectations. It will be part of the agenda for the Round Table on April 30.

We’ll also take a look at Robert Half (RHI) as a study candidate — but from the perspective of “traps” as community favorite RHI ends up in the “Look Out Below” roster this week along with Mylan Labs (MYL) and Novo Nordisk (NVO).

Materially Stronger: Biogen Idec (BIIB), Bristol-Myers Squibb (BMY), Kelly Services (KELYA), Albany Molecular (AMRI), BRE Properties (BRE), Public Storage (PSA), Investors Banc (ISBC)

Materially Weaker: Alcoa (AA), Anglogold Ashanti (AU), People’s United Financial (PBCT)

Market Barometers

The median Value Line low total return forecast is 6.7%, compared to 6.7% last week.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s